Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion

Kai Rejeski,Ariel Perez,Gloria Iacoboni,Viktoria Blumenberg,Veit L Bücklein,Simon Völkl,Olaf Penack,Omar Albanyan,Sophia Stock,Fabian Müller,Philipp Karschnia,Agnese Petrera,Kayla Reid,Rawan Faramand,Marco L Davila,Karnav Modi,Erin A Dean,Christina Bachmeier,Michael von Bergwelt-Baildon,Frederick L Locke,Wolfgang Bethge,Lars Bullinger,Andreas Mackensen,Pere Barba,Michael D Jain,Marion Subklewe,Veit L. Bücklein,Marco L. Davila,Erin A. Dean,Michael D. Jain
DOI: https://doi.org/10.1126/sciadv.adg3919
IF: 13.6
2023-09-24
Science Advances
Abstract:Prolonged cytopenias after chimeric antigen receptor (CAR) T cell therapy are a significant clinical problem and the underlying pathophysiology remains poorly understood. Here, we investigated how (CAR) T cell expansion dynamics and serum proteomics affect neutrophil recovery phenotypes after CD19-directed CAR T cell therapy. Survival favored patients with "intermittent" neutrophil recovery (e.g., recurrent neutrophil dips) compared to either "quick" or "aplastic" recovery. While intermittent patients displayed increased CAR T cell expansion, aplastic patients exhibited an unfavorable relationship between expansion and tumor burden. Proteomics of patient serum collected at baseline and in the first month after CAR-T therapy revealed higher markers of endothelial dysfunction, inflammatory cytokines, macrophage activation, and T cell suppression in the aplastic phenotype group. Prolonged neutrophil aplasia thus occurs in patients with systemic immune dysregulation at baseline with subsequently impaired CAR-T expansion and myeloid-related inflammatory changes. The association between neutrophil recovery and survival outcomes highlights critical interactions between host hematopoiesis and the immune state stimulated by CAR-T infusion.
multidisciplinary sciences
What problem does this paper attempt to address?